What is the cost of 300mg monthly prophylaxis of emicizumab for severe hemophilia A?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: December 2, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Cost of Emicizumab 300mg Monthly Prophylaxis

I cannot provide specific pricing information for emicizumab 300mg monthly prophylaxis as the evidence does not contain location-specific cost data or actual drug pricing figures.

What the Evidence Shows About Costs

The cost of emicizumab varies substantially across different healthcare systems globally, and specific pricing information is not standardized in clinical guidelines. 1, 2

Key Cost Considerations from Guidelines

  • Global cost variability is significant: The International Society on Thrombosis and Haemostasis (ISTH) explicitly acknowledges that emicizumab costs differ substantially across healthcare systems and may not be affordable or available in all countries 2

  • Availability limitations: Emicizumab may not be registered or available in some countries, limiting its use regardless of cost-effectiveness 1, 2

  • Shared decision-making required: Treatment selection should consider availability of products, costs, and patient preference when choosing between emicizumab and alternative therapies 1, 2

Cost-Effectiveness Evidence (Not Actual Pricing)

While I cannot provide actual costs, the evidence demonstrates cost-effectiveness in several countries:

  • France: Emicizumab was dominant (less costly and more effective), saving €234,191 over 5 years compared to bypassing agents 3

  • Canada: Total lifetime cost estimated at $26.2 million CAD for emicizumab versus $27.2 million for standard half-life FVIII 4

  • Korea: Emicizumab prophylaxis reduced costs by $2.6 million USD over a lifetime compared to on-demand bypassing agents 5

  • Iran: Emicizumab was dominant in patients with annual bleeding rates ≥18 6

Important Caveats

  • Hemophilia care represents substantial costs: Factor replacement therapy accounts for approximately 80% of overall hemophilia care costs 1, 2

  • Implementation challenges exist: The large costs involved in prophylaxis for severe hemophilia A with inhibitors create substantial barriers, particularly in low- and middle-income countries 1, 2

How to Obtain Actual Pricing

To determine the specific cost for your location, you must:

  • Contact the manufacturer (Genentech/Roche) directly for wholesale acquisition cost
  • Consult your local pharmacy benefit manager or specialty pharmacy
  • Review your specific insurance formulary and coverage policies
  • Contact your hemophilia treatment center for local pricing information

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Cost Considerations for Emicizumab in Hemophilia A Management

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Cost-utility analysis of emicizumab for the treatment of severe hemophilia A patients in Canada.

Haemophilia : the official journal of the World Federation of Hemophilia, 2023

Research

Cost-utility analysis of emicizumab prophylaxis in haemophilia A patients with factor VIII inhibitors in Korea.

Haemophilia : the official journal of the World Federation of Hemophilia, 2021

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.